The price of progress: Prescription drugs in the health care market

Health Affairs

Volumn 20, Issue 5, 2001, Pages 43-60

  Kleink, J D ^a  

^a Hlth Info Technol Res Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ECONOMICS; FEE; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; LEGAL ASPECT; MEDICAL CARE; ORGANIZATION AND MANAGEMENT; PHARMACOECONOMICS; REIMBURSEMENT; UNITED STATES;

ECONOMICS, PHARMACEUTICAL; FEES, PHARMACEUTICAL; HEALTH BENEFIT PLANS, EMPLOYEE; HEALTH CARE REFORM; HUMANS; MEDICAL ASSISTANCE; REIMBURSEMENT MECHANISMS; UNITED STATES;

EID: 0009655399     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.20.5.43     Document Type: Article

References (49)

1. T.A. Waidmann and K.G. Manton, "International Evidence on Disability Trends among the Elderly," 18 June 1998, 〈aspe.os.dhhs.gov/daltcp/reports/ trends.htm〉 (18 June 2001); and K. Manton et al., "Chronic Disability Trends in Elderly United States Populations: 1982-1994," Proceedings of the National Academy of Sciences USA 94 (March 1997): 2593-2598.
2. T.A. Waidmann and K.G. Manton, "International Evidence on Disability Trends among the Elderly," 18 June 1998, 〈aspe.os.dhhs.gov/daltcp/reports/ trends.htm〉 (18 June 2001); and K. Manton et al., "Chronic Disability Trends in Elderly United States Populations: 1982-1994," Proceedings of the National Academy of Sciences USA 94 (March 1997): 2593-2598.
3. Data collected from the National Heart Association; National Center for Health Statistics; and Centers for Disease Control and Prevention.
4. S.M. Foote and L. Etheredge, "Increasing Use of New Prescription Drugs: A Case Study," Health Affairs (JuI/Aug 2000): 165.
5. B.A. Weisbrod and C.L LaMay, "Mixed Signals: Public Policy and the Future of Health Care R&D," Health Affairs (Mar/Apr 1999): 116.
6. J.J. Barendregt, L. Bonneux, and P.J. van der Maas, "The Health Care Costs of Smoking," New England Journal of Medicine (9 October 1997): 15.
7. F. Lichtenberg, "Are the Benefits of Newer Drugs Worth Their Costs? Evidence from the 1996 MEPS," Health Affairs (Sep/Oct 01): 241-251.
8. Weisbrod and LaMay, "Mixed Signals," 121.
9. V.R. Fuchs, "Health Care for the Elderly: How Much? Who Will Pay for It?" Health Affairs (Jan/Feb 1999): 11.
10. D. Mechanic, "Muddling Through Elegantly: Finding the Proper Balance in Rationing," Health Affairs (Sep/Oct 1997): 83.
11. S.B. Soumerai and H.L. Lipton, "Computer-Based Drug-Utilization Review-Risk, Benefit, or Boondoggle?" New England Journal of Medicine (15 June 1995): 24.
12. Tufts Center for the Study of Drug Development, Outlook 2001 (Boston: Tufts University, 2001).
13. Ibid.
14. C. Petersen, "HMDs Get What They Pay For with HIV Treatment," Managed Healthcare (November 1999): 40.
15. J.M. Mitchell and K.H. Anderson, "Effects of Case Management and New Drugs on Medicaid AIDS Spending," Health Affairs (July/Aug 2000): 233.
16. Petersen, "HMOs Get What They Pay For," 42.
17. F. Lichtenberg, "Do (More and Better) Drugs Keep People Out of Hospitals?" American Economic Review (May 1996): 384-388.
18. Ibid.; Soumerai and Lipton, "Computer-Based Drug-Utilization Review"; and S.D. Horn et al., "Intended and Unintended Consequences of HMO Cost-Containment Strategies: Results from the Managed Care Outcomes Project," American Journal of Managed Care (March 1996): 253-264.
19. Ibid.; Soumerai and Lipton, "Computer-Based Drug-Utilization Review"; and S.D. Horn et al., "Intended and Unintended Consequences of HMO Cost-Containment Strategies: Results from the Managed Care Outcomes Project," American Journal of Managed Care (March 1996): 253-264.
20. Ibid.; Soumerai and Lipton, "Computer-Based Drug-Utilization Review"; and S.D. Horn et al., "Intended and Unintended Consequences of HMO Cost-Containment Strategies: Results from the Managed Care Outcomes Project," American Journal of Managed Care (March 1996): 253-264.
21. Soumerai and Lipton, "Computer-Based Drug-Utilization Review."
22. Horn, "Intended and Unintended Consequences."
23. Lichtenberg, "Do (More and Better) Drugs Keep People Out of Hospitals?"
24. Outlook 2001.
25. D.W. Moran, "Prescription Drugs and Managed Care: Can 'Free-Market Détente' Hold?" Health Affairs (Mar/Apr 2000): 70.
26. S. Lueck, "Spending on Prescription Drugs Rose 19 Percent," Wall Street Journal, 8 May 2001.
27. This number has been reported throughout the health care business press and has been conveyed to the author by numerous managed care executives and employer health care purchasers.
28. R. Rundle, "Calpers Rejects 2002 Health-Care Bids as Too High and Asks for Resubmission," Wall Street Journal, 23 February 2001.
29. Towers Perrin survey, as reported by C. Rauber, "Bruising Battles Ahead for Providers, HMDs," Modern Healthcare (15 February 1999): 52.
30. J.D. Kleinke, Bleeding Edge: The Business of Health Care in the New Century (Gaithersburg, Md.: Aspen Publishers, 1998).
31. S. Soumerai et al., "Payment Restrictions for Prescription Drugs under Medicaid: Effects on Therapy, Cost, and Equity," New England Journal of Medicine (27 August 1987): 550-556.
32. B. Stuart and C. Zacker, "Who Bears the Burden of Medicaid Drug Copayment Policies?" Health Affairs (Mar/Apr 1999): 208-210.
33. J.D. Kleinke, "Just What the HMO Ordered: Managed Care and the Paradox of Increasing Pharmacy Costs," Health Affairs (Mar/Apr 2000): 78-91.
34. Soumerai and Lipton, "Computer-Based Drug Utilization Review."
35. R.W. Dubois, "Explaining Drug Spending Trends: Does Perception Match Reality?" Health Affairs (Mar/Apr 2000): 240-247.
36. M. Chernew et al., "Pharmaceutical Cost Growth under Capitation: A Case Study," Health Affairs (Nov/Dec 2000): 266.
37. H.L. Lipton et al., "Managing the Pharmacy Benefit in Medicare HMDs: What Do We Really Know?" Health Affairs (Mar/Apr 2000): 52.
38. B. McCaughey-Ross, "How to Beat the High Cost of Aging," Wall Street Journal, 21 October 1999.
39. S. Soumerai et al., "Effects of a Limit on Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia," New England Journal of Medicine (8 September 1994): 650-655.
40. M. Edlin, "External Comparisons Help MCOs Get a Handle on Diabetes Costs," Managed Healthcare Executive (January 2001): 40.
41. Weisbrod and LaMay, "Mixed Signals," 116.
42. Lichtenberg, "Do (More and Better) Drugs Keep People Out of Hospitals?" 384.
43. L. Russell, Is Prevention Cheaper than a Cure? (Washington: Brookings Institution, 1987).
44. Numerous articles by Uwe Reinhardt, Paul Langley, Marc Berger, Robert Epstein, and the author.
45. M. Berger, "The Once and Future Application of Cost-Effective Analysis," Joint Commission Journal on Quality Improvement (September 1999): 455-461.
46. Mechanic, "Muddling Through Elegantly," 91.
47. E. Holve, L. Levitt, and J. Wang, "Employer Health Benefits 2000 Annual Survey" (Menlo Park, Calif.: Kaiser Family Foundation and Health Research and Educational Trust, 2000), 54.
48. Moran, "Prescription Drugs and Managed Care," 73.
49. Berger, "The Once and Future Application."